https://www.sciencedirect.com/science/article/pii/S030028962030288X
Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19
Summary:
This retrospective study of ivermectin use from Bangladesh which has authors from Bangladesh and Japan collected data on patients who had been previously treated into two arms:
115 received ivermectin plus standard care
133 received only standard care
Disease progression was better across the board for all metrics - ivermectin vs non-ivermectin:
Developed moderate respiratory distress - 3 (2.6%) vs 21 (15.8%) - p<0.001
Developed pneumonia - 0 (0%) vs 13 (9.8%)
Ischemic stroke - 0 (0%) vs 2 (1.5%)
Required intensive care management - 1 (0.9%) vs 11 (8.3%) - p<0.001
Clinical outcomes were better across the board for all metrics - ivermectin vs non-ivermectin:
Duration of viral clearance, median (IQR) – day - 4 (4–6) vs 15 (12–17) - difference: 9.78 (8.97–10.59) - p <0.001
Duration of hospital stay, median (IQR) - day - 9 (7–10) vs 15 (12–19) - difference: 6.3 (5.09–7.51) - p<0.001
Recovered and discharged - 114 (99.1) vs 124 (92.2) - difference: 0.516
Death - 1 (0.9%) vs 9 (6.8%)
Here is a video analysis of this paper/letter by Whiteboard Doctor:
https://www.youtube.com/watch?v=_UvZHJh_wdk
Ivermectin And COVID-19: New Study On Viral Clearance, Hospital Length Of Stay, And Mortality.
Here we will discuss a new study that was published out of Bangladesh in a Spanish Respiratory Medicine Journal called Archivos De Bronconumologia looking at Ivermectin for the treatment of COVID-19 in hospitalized patients. We will discuss what Ivermectin is, how it is theorized to work, and why it is being studied. We will then dive into the study including the doses of Ivermectin used, the study structure, the study population, and their findings. They found decreased development of moderate respiratory disease, decreased escalation to the intensive care unit, faster viral clearance (even compared to three other anti-virals), decreased length of stay in the hospital, and decreased mortality. Pretty impressive! What do these results mean? What are the limitations? Where to go from here? Check out the video for all the details and more!
[-] stereomatch | 1 points | Oct 13 2020 07:38:59
https://www.sciencedirect.com/science/article/pii/S030028962030288X Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19
Summary:
This retrospective study of ivermectin use from Bangladesh which has authors from Bangladesh and Japan collected data on patients who had been previously treated into two arms:
115 received ivermectin plus standard care
133 received only standard care
Disease progression was better across the board for all metrics - ivermectin vs non-ivermectin:
Developed moderate respiratory distress - 3 (2.6%) vs 21 (15.8%) - p<0.001
Developed pneumonia - 0 (0%) vs 13 (9.8%)
Ischemic stroke - 0 (0%) vs 2 (1.5%)
Required intensive care management - 1 (0.9%) vs 11 (8.3%) - p<0.001
Clinical outcomes were better across the board for all metrics - ivermectin vs non-ivermectin:
Duration of viral clearance, median (IQR) – day - 4 (4–6) vs 15 (12–17) - difference: 9.78 (8.97–10.59) - p <0.001
Duration of hospital stay, median (IQR) - day - 9 (7–10) vs 15 (12–19) - difference: 6.3 (5.09–7.51) - p<0.001
Recovered and discharged - 114 (99.1) vs 124 (92.2) - difference: 0.516
Death - 1 (0.9%) vs 9 (6.8%)
Here is a video analysis of this paper/letter by Whiteboard Doctor:
https://www.youtube.com/watch?v=_UvZHJh_wdk
Ivermectin And COVID-19: New Study On Viral Clearance, Hospital Length Of Stay, And Mortality.
Here we will discuss a new study that was published out of Bangladesh in a Spanish Respiratory Medicine Journal called Archivos De Bronconumologia looking at Ivermectin for the treatment of COVID-19 in hospitalized patients. We will discuss what Ivermectin is, how it is theorized to work, and why it is being studied. We will then dive into the study including the doses of Ivermectin used, the study structure, the study population, and their findings. They found decreased development of moderate respiratory disease, decreased escalation to the intensive care unit, faster viral clearance (even compared to three other anti-virals), decreased length of stay in the hospital, and decreased mortality. Pretty impressive! What do these results mean? What are the limitations? Where to go from here? Check out the video for all the details and more!
permalink